Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study.

BACKGROUND Emerging evidence on body composition suggests that sarcopenic obesity (obesity with depleted muscle mass) might be predictive of morbidity and mortality in non-malignant disease and also of toxicity to chemotherapy. We aimed to assess the prevalence and clinical implications of sarcopenic obesity in patients with cancer. METHODS Between Jan 13, 2004, and Jan 19, 2007, 2115 patients with solid tumours of the respiratory or gastrointestinal tract from a cancer treatment centre serving northern Alberta, Canada, were identified. Available lumbar CT images of the obese patients were analysed for total skeletal muscle cross-sectional area; these values were also used to estimate total body fat-free mass (FFM). FINDINGS Of the 2115 patients initially identified, 325 (15%) were classified as obese (body-mass index [BMI] > or =30). Of these obese patients, 250 had CT images that met the criteria for analysis. The remaining 75 patients were recorded as without assessable scans. Obese patients had a wide range of muscle mass. Sex-specific cut-offs that defined a significant association between low muscle mass with mortality were ascertained by optimum stratification analysis: 38 (15%) of 250 patients who had assessable CT images that met the criteria for analysis were below these cut-offs and were classified as having sarcopenia. Sarcopenic obesity was associated with poorer functional status compared with obese patients who did not have sarcopenia (p=0.009), and was an independent predictor of survival (hazard ratio [HR] 4.2 [95% CI 2.4-7.2], p<0.0001). Estimated FFM showed a poor association with body-surface area (r(2)=0.37). Assuming that FFM represents the volume of distribution of many cytotoxic chemotherapy drugs, we estimated that individual variation in FFM could account for up to three-times variation in effective volume of distribution for chemotherapy administered per unit body-surface area, in this population. INTERPRETATION This study provides evidence of the great variability of body composition in patients with cancer and links body composition, especially sarcopenic obesity, to clinical implications such as functional status, survival, and potentially, chemotherapy toxicity.

[1]  C. Begg,et al.  Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. , 1980, The American journal of medicine.

[2]  B. Heitmann,et al.  Mortality associated with body fat, fat-free mass and body mass index among 60-year-old Swedish men—a 22-year follow-up. The study of men born in 1913 , 2000, International Journal of Obesity.

[3]  D Kromhout,et al.  Reproducibility of performance-based and self-reported measures of functional status. , 1997, The journals of gerontology. Series A, Biological sciences and medical sciences.

[4]  R. Roubenoff.  Sarcopenic obesity: the confluence of two epidemics. , 2004, Obesity research.

[5]  R. Baumgartner.  Body Composition in Healthy Aging , 2000, Annals of the New York Academy of Sciences.

[6]  R. Roubenoff.  Sarcopenia: effects on body composition and function. , 2003, The journals of gerontology. Series A, Biological sciences and medical sciences.

[7]  A. Astrup,et al.  Obesity : Preventing and managing the global epidemic , 2000 .

[8]  R. Bellantone,et al.  Therapy of muscle wasting in cancer: what is the future? , 2004, Current opinion in clinical nutrition and metabolic care.

[9]  Joseph R. Bertino,et al.  Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. , 1980, The American journal of medicine.

[10]  A. Stunkard,et al.  The accuracy of self-reported weights. , 1981, The American journal of clinical nutrition.

[11]  N. Pavlakis,et al.  The predictive value of body protein for chemotherapy‐induced toxicity , 2000, Cancer.

[12]  A. Tjønneland,et al.  Body fat and fat-free mass and all-cause mortality. , 2004, Obesity research.

[13]  S. Heymsfield,et al.  Human body composition and the epidemiology of chronic disease. , 1995, Obesity research.

[14]  Sumithra J. Mandrekar,et al.  Finding Optimal Cutpoints for Continuous Covariates with Binary and Time-to-Event Outcomes , 2006 .

[15]  Stanley Heshka,et al.  Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. , 2004, Journal of applied physiology.

[16]  N. Aaronson,et al.  Effect of a protein and energy dense n-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial , 2003, Gut.

[17]  S. Klein,et al.  Physical frailty and body composition in obese elderly men and women. , 2004, Obesity research.

[18]  T. Byers,et al.  THE VALIDITY OF SELF‐REPORTS OF PAST BODY WEIGHTS BY U.S. ADULTS , 1995, Epidemiology.

[19]  K. Westerterp,et al.  Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, nonhormone‐sensitive cancer , 1998, Cancer.

[20]  F. Piette,et al.  Sarcopenia is predictive of nosocomial infection in care of the elderly , 2006, British Journal of Nutrition.

[21]  M Ferguson,et al.  Use of the scored Patient-Generated Subjective Global Assessment (PG-SGA) as a nutrition assessment tool in patients with cancer , 2002, European Journal of Clinical Nutrition.

[22]  C. Pichard,et al.  Increased length of hospital stay in underweight and overweight patients at hospital admission: a controlled population study. , 2005, Clinical nutrition.

[23]  S. Heymsfield,et al.  Epidemiology of sarcopenia among the elderly in New Mexico. , 1998, American journal of epidemiology.

[24]  Tony Reiman,et al.  Body Composition as an Independent Determinant of 5-Fluorouracil–Based Chemotherapy Toxicity , 2007, Clinical Cancer Research.

[25]  Abdulmajeed Al Abdukareem.  Randomized, placebo-controlled trial , 2004, Annals of Saudi medicine.

[26]  Ronenn Roubenoff,et al.  From the Chicago MeetingsSarcopenia , 2001 .

[27]  S B Heymsfield,et al.  Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. , 1998, Journal of applied physiology.

[28]  M. Winslet,et al.  Diet and colorectal cancer: implications for the obese and devotees of the Atkins diet , 2005, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[29]  D. Allison,et al.  Years of life lost due to obesity. , 2003, JAMA.

[30]  F. Greene.  AJCC cancer staging handbook , 2002 .

[31]  R. Baumgartner,et al.  Sarcopenic obesity predicts instrumental activities of daily living disability in the elderly. , 2004, Obesity research.

[32]  P. Stenvinkel,et al.  Obese sarcopenia in patients with end-stage renal disease is associated with inflammation and increased mortality. , 2007, The American journal of clinical nutrition.